A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)
Latest Information Update: 17 Dec 2024
At a glance
- Drugs Cytarabine (Primary) ; Daratumumab (Primary) ; Daratumumab/hyaluronidase (Primary) ; Methotrexate (Primary) ; Methotrexate (Primary) ; Pegaspargase (Primary) ; Vincristine (Primary)
- Indications Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 12 Dec 2024 Planned End Date changed from 31 Oct 2024 to 30 Jun 2027.
- 12 Dec 2024 Planned primary completion date changed from 31 Oct 2024 to 30 Jun 2027.
- 18 Dec 2023 Planned End Date changed from 1 Oct 2024 to 31 Oct 2024.